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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not probiotics 
are safe and effective in reducing the incidence of diarrhea in HIV-positive individuals. 
 
Study Design: Systematic review of three English language primary studies, published in 1998, 
2007, and 2008. 
 
Data Sources: Three double-blind, randomized, controlled trials published after 1996, comparing 
administration of probiotics with placebo, were obtained using EBSCOhost, PubMed, and 
Cochrane databases. 
 
Outcomes Measured: Frequency and consistency of stools.  Daily or weekly questionnaires 
allowed subjects to report perceived severity of symptoms using scales containing descriptive 
words and figures with corresponding numeric values. Subjects were evaluated initially at 
baseline and subsequently at the completion of the studies, and the results were compared. 
 
Results:  No intervention-related negative side effects or adverse events were reported in any of 
the studies.  Anukam and colleagues found that those women treated with probiotics had rapid 
resolution of diarrhea compared to controls, for both the duration of treatment at day fifteen and 
at follow-up on day ninety.  Trois, et al. reports a decrease in loose stools and an increase in 
normal stools in both groups but no statistically significant decrease in diarrhea in the probiotic 
group as compared with control.  
 
Conclusion: All three studies showed that probiotics are safe when used in children and adults 
with HIV/AIDS.  Simple comparison of the studies performed by Trois, et al. and Anukam, et al. 
suggests that probiotic supplements are more efficacious in adult populations than pediatric 
populations in reducing frequency of loose stools.  However, the use of anti-retroviral drugs, 
geographic location, probiotic bacterial strain, and the cause of diarrhea in these populations may 
have impacted the outcomes.  More studies containing larger patient sample sizes and including 
those in various other countries should be performed to further determine the efficacy of 
probiotics in reducing diarrhea and appreciate other health benefits in diverse populations of 
HIV-positive individuals. 
 
Key words: probiotics, safety, diarrhea, gastrointestinal, children, adults, HIV, AIDS 
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INTRODUCTION 
Diarrhea, in both acute and chronic forms, is one of the most common symptoms 
experienced by men, women, and children who have been infected with the human 
immunodeficiency virus (HIV).1 In its earliest days, HIV/AIDS was described as the “slim 
disease” due to advanced wasting and persistent diarrhea, which is still a reality in Africa and 
other disadvantaged parts of the world.  Diarrhea also contributes as a major cause of morbidity 
and mortality for HIV-positive children across the globe.2 Chronic diarrhea is often defined as 
three or more loose or liquid stools per day for more than four weeks and/or a daily stool weight 
greater than 200 g/day.  While acute diarrhea is associated with more pain, blood stream 
invasion, and death for HIV patients, both acute and chronic forms of diarrhea threaten overall 
health and quality of life.1 
 Despite increased research efforts and education aimed at eradicating HIV-transmission, 
2.6 million new infections are reported worldwide yearly, with 50,000 of these occurring in the 
United States.3 The care of HIV-positive individuals in the US is of great cost; for example, 
Farquhar, et al. estimated $18.2 billion in HIV-associated economic losses in 2001 alone.4 One 
study in Birmingham, Alabama cites costs between $13,885 and $36,532 per HIV patients per 
year.5   The chief expenses are generated by medication costs (71-84%) and care for those with 
more advanced disease. 
Physician Assistants (PAs) are often the sole care provider for HIV-patients.  As of 2005, 
PAs and Nurse Practitioners (NPs) provided most of the care for 20% of CARE Act Title III HIV 
clinics.  PAs and NPs performed similarly to those physicians trained in infectious disease and 
superiorly to generalist non-HIV experts in 6 of 8 quality measures.6 Therefore, PAs play an 
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important role in the management of HIV in the US and particularly in maintaining quality and 
specificity of care for these patients.   
HIV-related diarrhea is multi-factorial in nature.  Infectious and non-infectious causes 
prevail, yet all physiological aspects are not fully understood.  While they are found in the 
serum, the majority of CD4+ T-lymphocytes reside in the mucosal surfaces, particularly the gut.  
The intestinal mucosa acts a main target for HIV as well as a “reservoir” for viral replication, 
especially in early disease, leading to immune dysregulation through increased apoptosis of 
CD4+ lymphocytes.1 Bacterial overgrowth, opportunistic infection, and malabsorption of 
nutrients can also result.  Numerous infectious agents are often isolated in stool cultures, 
including bacterial species (E. coli, Salmonella, Shigella, C. difficile, Mycobacterium, 
Campylobacter), viruses (Rotavirus, adenovirus, Cytomegalovirus), protozoan parasites (Giardia 
lamblia, Entamoeba histolytica, Cryptosporidium parvum,), and fungi (Candida, 
Histoplasmosis).1   
Even in the absence of infection, the HIV virus itself causes “profound changes” in the 
intestinal mucosa.1 Increased permeability allows for translocation of microbial products across 
the gut, which may stimulate innate immune receptors.  Villous atrophy and crypt hyperplasia of 
the jejunum are common findings, termed, “HIV enteropathy.”  Decreased absorption of sugars, 
vitamin B12, and other nutrients are linked with chronic diarrhea in HIV patients.  Malabsorption 
is known to directly affect the CD4 count in HIV children adversely.2 The virus is also 
associated with inflammatory bowel disease, pancreatic disease (impaired fat absorption), and 
lymphomas including Hodgkin and Non-Hodgkin B-cell, diffuse large B-cell, primary effusion 
lymphoma, Burkitt and Burkitt-like lymphomas, and Kaposi sarcoma, all of which have the 
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potential for gastrointestinal (GI) symptoms.1 Additionally, diarrhea is one of the most common 
side effects of most antiretroviral therapies (ARTs).7 
No specific treatment or drug has been approved for HIV-related diarrhea.  The main 
goals of treatment are to eradicate pathogenic causes, reduce the number of loose stools per day, 
manage dehydration, decrease abdominal discomfort, and improve quality of life.7 Antibiotics, 
anti-virals, and anti-fungals should be given based on the sensitivity of suspected or isolated 
pathogens.  While ARTs have helped to decrease chronic diarrhea in Western populations, 
practitioners have commonly prescribed antimotility agents, such as loperamide, diphenoxylate, 
and codeine, or adsorbents like bismuthsabsalicylate, kaolin/pectin, and attapulgite to control 
symptoms.  Cholestyramine (for malabsorption of bile salts) and thalidomide (for HIV-related 
colitis) have also been employed.   Supplementation with vitamin A and zinc have been shown to 
reduce gut permeability.1 
Probiotics are defined by the Food and Agricultural Organization (FAO) as “live micro- 
organisms which when administered in adequate amounts confer a health benefit on the host”8.  
Supplementation has been shown to enhance mucosal immune defense by supporting 
macrophages, killer cells, T cells and interferon, and acting against pathogenic colonization and 
translocation.2 Their use has been well documented in the alleviation of diarrhea (Lactobacillus 
sp) and other unwanted GI symptoms.  Probiotics, L. reuteri in particular, have been beneficial in 
prophylaxis against cryptosporidiosis, a common pathogen in the HIV population.8 The probiotic 
organisms do not remain for extended periods of time in the GI tract, so sufficient quantities 
(>1x107/day) are necessary to maintain colonization and immune stimulation.2 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not probiotics are 
safe and effective in reducing the incidence of diarrhea in HIV-positive individuals. 
METHODS 
 A number of criteria were considered in selection of studies. The population was limited 
to HIV-positive individuals two years old or greater who experience diarrhea.  Only double blind 
or double-masked, randomized, controlled trials that introduced probiotic supplementation as 
compared with visually-matched placebo were considered.  The following strains were deemed 
acceptable probiotics: Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium 
bifidum, and Lactobacillus reuteri.  Outcomes of interest included tolerance, adverse events, and 
consistency and frequency of stools. 
 A detailed search was performed by the author of this review between January 2011 and 
February 2011 using the Cochrane Library EBM Online Database and PubMed Online, with the 
key words “HIV,” “diarrhea,” and “probiotics.”  All three articles that were selected to be 
included in this review were written in the English language and published in peer-reviewed 
journals between 1996 and present.  Selection of studies, which was also performed by the 
author, was based on relevance to the topic of interest, and only studies that reported patient-
oriented outcomes (Patient Oriented Evidence that Matters, or POEMs) were accepted.  Inclusion 
criteria simply included HIV-positive status.  Exclusion criteria included individuals with other 
chronic diseases, known food or drug allergies, pregnancy, recent (<1 month) changes in ART or 
changes during the study.  The studies either reported p-values or contained dichotomous data, 
which could be used to calculate Relative Risk Reduction/Increase (RRR/RRI), Absolute Risk 
Reduction/Increase (ARR/ARI), and Numbers Needed to Treat/Harm (NNT/NNH).  
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Demographics of the three final selections are reported and displayed in Table 1. 
 Table 1. Demographics and characteristics of included studies  
Study Type # of 
patients 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Intervention 
Anukam, 
20089 
Double-
blind, 
RCT 
24 18-44 HIV (+) 
females age 
18-44, 
CD4>200 
cells/mcL 
Lactose 
intolerance, 
currently 
taking 
supplements 
or ARTs 
2 100mL 
conventional 
yogurt/day 
fermented with 
Lactobacillus 
delbruekii subsp. 
Bulgaris and 
Streptococcus 
thermophilus 
supplemented 
with L. 
rhamnosus GR-1 
and L. reuteri 
RC-14 at 107/mL 
Trois, 
20082 
Double-
blind, 
RCT 
77 2-12 HIV (+) 
children 
who 
acquired 
the disease 
perinatally, 
one child 
who 
acquired by 
blood 
products  
Chronic 
diseases or 
allergies; 
Changes in 
ART in past 
3 months or 
during the 
study 
1 14g/day of a 
standard formula 
containing 
Bifidobacterium 
bifidum and 
Streptococcus 
thermophilus at 
2.5 x 1010 CFU 
diluted in 100 mL 
of milk 
Wolf, 
199810 
Double-
blind, 
RCT 
39 18-65 HIV(+) 
males and 
non-
pregnant 
females (at 
least 6 
weeks post-
partum); 
CD4 count 
>400 
Known drug 
or food 
allergy; 
Individuals 
taking any 
ART other 
than 
Zidovudine 
4 1010 CFU 
Lactobacillus 
reuteri (strain 
SD2112)/day in a 
beverage <37°C 
[ex: tap water, 
milk, orange juice 
from concentrate, 
apple juice, grape 
juice, cranberry 
juice, 7-up] 
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OUTCOMES 
 All three studies ascertained POEMs by gathering reports from participants.  Wolf, et al. 
were concerned mainly with safety and tolerance of probiotics.  A review of systems was taken 
at baseline for comparison of the efficacy of implemented therapy.  By completing daily 
questionnaires, subjects reported the severity of diarrhea using the following scale: 0 = absent, 
1= mild, 2 = moderate, and 3 = severe; subjects also reported the number of bowel movements 
daily and the consistency using the following scale: 1 = hard, dry; 2 = hard, formed; 3 = soft, 
formed; 4 = soft, unformed; 5 = watery.10  Trois, et al. also used previously approved reference 
questionnaires, which were completed by the subjects’ parents, to determine the frequency and 
consistency of stools in each 24-hour period.  Drawings depicting stools varied from watery to 
normal and had corresponding numeric scores.2  Anukam, et al. developed a structured 
questionnaire given at baseline, fifteen days, thirty days, and three months.  Participants rated 
diarrhea episodes as absent, moderate (daily episodes of watery stools), or severe (persistent 
watery stools, urgency and frequency of defecation).9 
RESULTS 
Safety.  Results of all three studies support the safety of using various probiotics in HIV 
patients.  Wolfe, et al. found no statistically significant difference (p<0.05) in the frequency and 
consistency of stools between the control group and those receiving 1010 colony-forming units 
(CFU) of L. reuteri per day during any week of the study.  Baseline values were not reported, 
and results were presented based on percent of subject days.  Using this method, most GI 
tolerance factors were absent for the majority (>80%) of study days (See Table 2).  No p-values 
were reported for these.  Both groups reported a greater amount of flatulence, but those receiving 
probiotics experienced less.  A potential side effect, mild or moderate nausea, was reported by 
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18.26% of the probiotic group, as compared with only 6.72% of the control group.  However, 
those taking probiotics reported no significant vomiting or reflux.  The experimental group also 
reported slightly higher, but not statistically significant, incidence of constipation and distention; 
these were still absent 93.31% and 86.08% of the time, respectively.  All data was continuous, 
rather than dichotomous, and no baseline values were reported for comparison or for further 
calculations.  Results are reported in Table 3.  Anukam, et al. saw no adverse effects in the 
probiotic group, including any significant change in key lab values—total WBCs, neutrophils, 
lymphocytes, RBCs, hemoglobin, hematocrit, or platelet count (see Table 4)—while three in the 
control group experienced rashes during the study.  Trois et al. did not report any adverse 
reactions in the children studied. 
Table 2. GI tolerance factors of L. reuteri reported by Wolfe, et al., 199810 
 
 
 
 
 
 
 
*Results reported in percentage of subject-days 
Table 3. Safety and Tolerance of L. reuteri reported by Wolfe, et al.,199810 
 Week 1 Week 2 Week 3 Week 4 Week 5 
Frequency NSa NS NS NS NS 
Consistencyb NS NS NS NS NS 
aP-values represent the level of significance for each week comparing placebo with L. reuteri; 
NS = not significant (p>0.05). 
bFecal consistency score: 1 = hard, dry; 2 = hard, formed; 3 = soft, formed; r = soft, unformed; 5 
= watery. 
 
Parameter Treatment Absent Mild Moderate Severe 
Flatulence Placebo L. reuteri 
62.89* 
67.45 
23.67 
19.53 
12.89 
9.4 
0.56 
3.62 
Nausea Placebo L. reuteri 
93.14 
81.56 
5.46 
14.1 
1.26 
4.16 
0.14 
0.18 
Vomiting Placebo L. reuteri 
99.58 
97.47 
0.28 
1.99 
0.14 
0.54 
0.0 
0.0 
Reflux Placebo L. reuteri 
95.66 
94.21 
3.78 
4.88 
0.42 
0.9 
0.0 
0.14 
Constipation Placebo L. reuteri 
97.06 
93.31 
1.82 
3.62 
1.12 
1.27 
0.0 
1.81 
Distention Placebo L. reuteri 
91.32 
86.08 
3.92 
7.96 
4.62 
2.71 
0.14 
3.25 
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Efficacy. The success of probiotic supplementation in reducing diarrhea varied 
significantly between the trials.  Anukam, et al. studied adult females living in Nigeria and used 
conventional yogurt fermented with Lactobacillus delbruekii subsp. bulgaris and Streptococcus 
thermophilus and supplemented with 2.5x109 CFU/day of L. rhamnosus, GR-1 and L. reuteri 
RC-14.  All participants admitted to moderate diarrhea at baseline.  The authors saw a “complete 
resolution” of diarrhea in 12/12 women in the experimental group by the second day of the 
study, which lasted for the remainder of the treatment period (day 15), as compared with only 
one control group participant.  At the ninety-day follow-up, 8/12 that received the probiotics still 
reported a total absence of diarrhea, while only 2/12 of those in the control group reported its 
absence.  Risk and treatment statistics are summarized in Table 4.  
Table 4. Diarrhea reduction with L. reuteri and L. rhamnosus reported by Anukam, et al., 20089 
 RBIa ABIa NNT a Adverse Eventsb 
Day 2 of treatment c 100% 1 subject NR, NSd 
Day 15 (full duration of treatment) 10.1 91% 2 subjects NR, NS 
Day 90 (post-treatment follow-up) 2.99 50% 3 subjects NR, NS 
aRBI = Relative benefit increase; ABI = Absolute benefit increase; NNT = Numbers needed to 
treat 
bAdverse events in those receiving probiotics; NR = none reported; 
CCould not be calculated 
dNS = not significant; pertaining to p-values (all >0.05) comparing laboratory values at baseline 
and day 30 for the following hematologic parameters: TWBC, neotrophils, lymphocytes, RBCs, 
HB, HCT, MCV, MCH, MCHC, RDW, and platelets 
 
Trois, et al. did not see the same overwhelming efficacy with the children studied in 
Brazil.  Those in the experimental group received 2.5x1010 CFU of Bifidobacterium bifidum and 
Streptococcus thermophilus.  Both groups experienced a statistically significant (p<0.05) 
decrease in number of liquid stools and an increase number of in normal stools.  Notably, no 
statistical difference existed between the groups.  Results of this study are presented in Table 5. 
Children under age 2 or greater than 12 years were excluded from participating in this study.  
Only one subject in the probiotics group did not adhere to the treatment regimen yet was still 
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included in the results due to his or her intention to be treated.  One subject in the control group 
became hospitalized and was removed entirely from the study.  Overall, the adults who received 
L. rhamnosus and L. reuteri experienced greater resolution of diarrhea than did the children who 
received B. bifidum and S. thermophilus. 
Table 5. Changes in stool with B. bifidum and S. thermophilus reported by Trois, et al., 20072 
Outcome measured p from 
baselinea  
Significance p between 
groups 
Significanceb 
Decrease in # if liquid stools 0.006  Significant 0.522 NSc 
Decrease in # of loose-soft stools 0.955 NS Not reported  
Increase in # of normal stools 0.001 Significant 0.199 NS 
ap-values from baseline were reported to be statistically the same in both placebo and group 
receiving Bifidobacterium bifidum and Streptococcus thermophilus when compared with 
respective baseline values. 
bStatistical significance of p-value comparison between treatment groups 
cNS = Not significant; a p-value is deemed significant if <0.05. 
 
DISCUSSION 
 The author was unable to find another systematic review written to date concerning the 
use of probiotics to alleviate HIV-related diarrhea.  The study performed by Wolfe, et al. was the 
pioneer trial to test and prove the safety of probiotics in HIV-positive patients.  The study by 
Anukam, et al. showed great reduction of diarrhea but may be limited by a sample size of only 
twelve subjects in each group, experimental and control, who were not using any ART.  The 
subjects in Trois, et al. were using ART, which is notorious for producing the adverse effect of 
diarrhea.  This difference could contribute to the discrepancy in results.  Anukam, et al. only 
provided fifteen days of treatment, while Trois provided 60 days.  It has been noted that the 
effects of probiotics differ and are unique to each strain.8 The women in Nigeria were given L. 
rhamnosus and L. reuteri, while the children in Brazil were given B. bifidum and S. 
thermophilus. These differences could also be contributing to such varied results.  The nature of 
the diarrhea in each subject was not ascertained before beginning the studies, so the exact 
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mechanisms by which the probiotics were functioning in alleviating or not alleviating diarrhea 
could not be determined for certain. 
Supplementation with probiotics continues to be an area of intense research for HIV and 
many other conditions.  Multiple studies have shown that probiotics also effectively increase the 
CD4 count in people with HIV/AIDS.9,11 Strong evidence exists to support benefits against acute 
diarrhea from rotavirus and in preventing surgical complications like pouchitis.  Other areas that 
have been explored are prevention of necrotizing enterocolitis (NEC), traveler’s diarrhea, H. 
pylori infection, the control of irritable bowel syndrome (IBS), inflammatory bowel disease 
(IBD), reducing the risk of bladder and colon cancer, vulvovaginal candidiasis and other 
urogenital problems, respiratory infections, atopic conditions, and dental caries.8,12  
The most common side effects noted across studies have been flatulence and bloating, 
which are not considered dangerous and are usually mild.8  Wolfe, et al. noted both of these to be 
present in subjects of that study.10  While they have never been proven in a clinical trial, the most 
serious potential adverse events are bacteremia and fungemia, which have been documented in 
the past as isolated cases.  These are extremely rare, estimated 1 in 1 million and 1 users in 1.69 
million users, respectively; yet the severely immunocompromised are considered among those at 
highest risk.8 Probiotic use has also been associated with increased mortality in patients with 
severe acute pancreatitis.  Lactobacillus preparations are contraindicated for those with a 
hypersensitivity to lactose or milk, and S. boulardii for patients with yeast allergies.  Currently, 
no contraindications for Bifidobacteria exist.  Probiotics are available as supplements (i.e., 
tablets, capsules, or powders) or as fermented dairy products (i.e., yogurt and milk) and have not 
yet been evaluated by the FDA for the creation of specific recommendations or regulations.8 
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CONCLUSION 
The articles reviewed demonstrate that probiotic supplementation is safe in HIV patients, 
but the evidence is conflicting regarding its efficacy in reducing the incidence of diarrhea in this 
population.   No adverse events were attributed to probiotic use.  The evidence provided by 
Aunkam, et al. is promising and is reason enough to pursue the intervention further.  The Food 
and Agriculture Organization (FAO) and World Health Organization (WHO) published a 2001 
Report on Probiotics that recommended “efforts be made to take probiotics to developing 
countries.”13 Motivated by the work of Anukam, et al., a group called Western Heads East 
(WHE) has created a community kitchen in Mwanza, Tanzania for producing a probiotic yogurt 
named Fiti, which uses L. rhamnosus GR-1.  Trials have been completed but not yet published, 
which showed fewer episodes of diarrhea in HIV-positive individuals who received Fiti yogurt 
(p<0.01 in one trial and p=0.05 in another).13  Future trial designs should include control groups 
of adults who are using ART to determine the benefits to this segment of the HIV population, as 
ART is becoming more available.  Because probiotics are relatively inexpensive, widely 
available, and generally safe, trials such as these should continue, especially in children and 
adults of impoverished areas around the globe, in order to aid these individuals and to expand 
what is known about the various benefits of probiotic supplementation.
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